

Patterns of physical activity progression in patients with COPD

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	2 (abstract page) of main text
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2 (abstract page) of main text
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4 of main text
Objectives	3	State specific objectives, including any prespecified hypotheses	4-5 of main text
Methods			
Study design	4	Present key elements of study design early in the paper	5 of main text
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5 of main text
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	5 of main text
		(b) For matched studies, give matching criteria and number of exposed and unexposed	Not applicable
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6-7 of main text
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6-7 of main text
Bias	9	Describe any efforts to address potential sources of bias	7-8 of main text, 2-3 of supplementary material
Study size	10	Explain how the study size was arrived at	3 of supplementary material
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	7-8 of main text, 2-3 of supplementary material
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	7-8 of main text, 2-3 of supplementary material
		(b) Describe any methods used to examine subgroups and interactions	7-8 of main text, 2-3 of supplementary material
		(c) Explain how missing data were addressed	7, 22-23 (Table 1) and 24-25 (Table 2) of main text; 5-7 (Tables S1 and S2) of supplementary material

		(d) If applicable, explain how loss to follow-up was addressed	7 of main text; 2, 4 (Figure S1) of supplementary material
		(e) Describe any sensitivity analyses	8 of main text, 2-3 of supplementary material
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram	8 of main text; 4 (Figure S1) of supplementary material 4 (Figure S1) of supplementary material 4 (Figure S1) of supplementary material
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) Summarise follow-up time (eg, average and total amount)	8-10 and 22-23 (Table 1) of main text 22-25 (Tables 1 and 2) of main text, 5-7 (Tables S1 and S2) of supplementary material 8-10 of main text (Figures 1 and 2), 24-25 of main text (Table 2), 7 (Table S2 of supplementary material)
Outcome data	15*	Report numbers of outcome events or summary measures over time	8-10 and 24-26 of main text, (Tables 2 and 3)

Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	8-10 and 24-26 of main text (Tables 2 and 3) 8-10 and 24-26 of main text (Tables 2 and 3) Not applicable
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	9-10 of main text, 8-10 (Tables S3-S5) of supplementary material
Discussion			
Key results	18	Summarise key results with reference to study objectives	10 of main text
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	14 of main text
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	10-15 of main text
Generalisability	21	Discuss the generalisability (external validity) of the study results	13 of main text
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	6 of authorship page